Overview

We utilize our proprietary computational target discovery platform to identify novel drug targets and pathways and develop first-in-class therapeutics designed to address the unmet need in cancer immunotherapy. Our drug and clinical development processes are guided by a deep understanding of the biology of these novel pathways to identify optimal drug combinations and design a robust biomarker strategy for patient selection.

Compugen's Pipeline Program

 

 

COM701 / PVRIG COM701 + Opdivo BAY 1905254 BAY 1905254 + Keytruda COM902 / TIGIT Bi-specific products Multiple myeloid programs

APPLY TO THIS POSITION


Max 1mb, accepted formats: pdf, doc, docx, rtf
[recaptcha size:compact]
Message Sent. Thank You!